XLO XILIO THERAPEUTICS INC Capital Structure Changes 8-K Filing 2024 - Stock Sale Agreement Xilio Therapeutics has sold approximately $25 million in common stock and prefunded warrants to Gilead Sciences through multiple private placements, with initial proceeds of $13.5 million from 6,860,223 shares at $1.97 each, and additional sales bringing total gross proceeds to $25 million. The company also announced preliminary Phase 1 clinical trial data for its drug XTX101 and expects its cash to fund operations into Q3 2025.Get access to all SEC 8-K filings of the XILIO THERAPEUTICS INC